-
EFFICACY AND SAFETY OF FIRST-LINE TREATMENT STRATEGIES IN RAS/KRAS-MUTATED METASTATIC COLORECTAL CANCER: A SYSTEMATIC LITERATURE REVIEW
Aug 11, 2026, 17:16 PM -
HOW MANY PICOS IS TOO MANY? QUANTIFYING THE EVIDENCE BURDEN OF THE EU JOINT CLINICAL ASSESSMENT
Aug 11, 2026, 17:16 PM -
GEOGRAPHIC ACCESS TO HEALTHCARE AMONG OLDER ADULTS: NATIONAL ESTIMATES OF TRAVEL BURDEN IN MEDICARE
Aug 11, 2026, 17:16 PM -
LONG-TERM REDUCTION IN PATIENT-REPORTED BLOOD-IN-STOOL ENTRIES ON ADALIMUMAB IN ULCERATIVE COLITIS: REAL-WORLD EVIDENCE FROM THE AMPERSAND DIGITAL COHORT
Aug 11, 2026, 17:16 PM -
LOW ON AGENCY, HIGH ON BURNOUT: A NATIONAL CROSS-SECTIONAL STUDY AMONG PHARMACY ASSISTANTS AND TECHNICIANS DURING THE INITIAL STAGES OF THE NOVEL CORONAVIRUS (COVID-19) PANDEMIC IN HUNGARY
Aug 11, 2026, 17:16 PM -
ESTIMATING THE POTENTIAL COST SAVINGS OF GERIATRIC ASSESSMENT AND MANAGEMENT (GAM) FOR OLDER ADULTS RECEIVING SYSTEMIC CANCER THERAPY IN JAPAN: A SCENARIO-BASED ANALYSIS
Aug 11, 2026, 17:16 PM -
BIUXX
Aug 11, 2026, 17:16 PM -
COMPARATIVE EVALUATION OF GRAPH RETRIEVAL-AUGMENTED GENERATION (GRAPHRAG) AND CONVENTIONAL RAG FOR EVIDENCE SYNTHESIS
Aug 11, 2026, 17:16 PM -
COST-EFFECTIVENESS OF OBINUTUZUMAB FOR THE TREATMENT OF ACTIVE LUPUS NEPHRITIS IN THE UK
Aug 11, 2026, 17:16 PM -
CLINICAL MONITORING AND HCRU AMONG INDIVIDUALS WITH CHRONIC HEPATITIS B IN THE UK: A PHYSICIAN-REPORTED RETROSPECTIVE REAL-WORLD ANALYSIS
Aug 11, 2026, 17:16 PM -
EPIDEMIOLOGY AND DISEASE BURDEN OF DERMATOMYOSITIS IN GERMANY - FIRST EXPERIENCES WITH THE HEALTH DATA LAB IN A NATIONWIDE RETROSPECTIVE CLAIMS DATA ANALYSIS
Aug 11, 2026, 17:16 PM -
THE TREAT-LATE EQUILIBRIUM IN CHRONIC KIDNEY DISEASE BEHAVIORAL ECONOMICS OF A $228 BILLION FISCAL BURDEN
Aug 11, 2026, 17:16 PM -
UNDERSTANDING DIETS FROM THE ROOTS: OPPORTUNITIES AND LIMITATIONS IN THE INFODEMIOLOGICAL ANALYSIS OF INFORMATION-SEEKING BEHAVIOR REGARDING MACRONUTRIENTS IN THE HUNGARIAN POPULATION
Aug 11, 2026, 17:16 PM -
ECONOMIC BURDEN BEFORE AND AFTER SJOGREN'S DISEASE DIAGNOSIS IN THE US: A RETROSPECTIVE CLAIMS-BASED ANALYSIS
Aug 11, 2026, 17:16 PM -
PHARMACEUTICAL PAYBACK BURDEN AND HEALTH TECHNOLOGY ASSESSMENT (HTA) MATURITY ACROSS EU MEMBER STATES: A SCOPING REVIEW
Aug 11, 2026, 17:16 PM -
IMPACT OF THE NEW UK EQ-5D-5L VALUE SET ON HEALTH STATE UTILITY VALUES: A MULTI-COUNTRY COMPARISON ACROSS DISEASE GROUPS
Aug 11, 2026, 17:16 PM -
THE IMPACT OF CAREGIVING FOR PEOPLE WITH AUTOIMMUNE NEUROMUSCULAR DISORDERS (ANMD): A LITERATURE REVIEW
Aug 11, 2026, 17:16 PM -
SOCIOECONOMIC BURDEN OF TYPE 1 SMA IN JAPAN: COMPARING THE IMPACT OF ONASEMNOGENE ABEPARVOVEC, NUSINERSEN AND RISDIPLAM ON PATIENTS AND CAREGIVERS
Aug 11, 2026, 17:16 PM -
COST-EFFECTIVENESS OF BEMPEDOIC ACID AS ADJUNCT TO STANDARD OF CARE (SOC) THERAPY IN AUSTRALIA FOR THE TREATMENT OF ADULTS WITH HYPERCHOLESTEROLAEMIA CLASSIFIED AS EITHER HIGH-RISK PRIMARY OR SECONDARY PREVENTION
Aug 11, 2026, 17:16 PM -
DECODING PECAN: WHAT EARLY FRENCH ASSESSMENTS REVEAL ABOUT MARKET ACCESS FOR DIGITAL MEDICAL DEVICES
Aug 11, 2026, 17:16 PM
